Immunocore Holdings plc (IMCR)
NASDAQ: IMCR · Real-Time Price · USD
32.42
+0.69 (2.17%)
At close: Nov 10, 2026, 4:00 PM EST
32.38
-0.04 (-0.12%)
After-hours: Nov 10, 2026, 4:10 PM EST
Immunocore Holdings Revenue
In the year 2025, Immunocore Holdings had annual revenue of $400.02M with 28.95% growth. That makes Immunocore Holdings the 12,182nd largest company in the world by revenue and 2,390th in the United States.
Revenue (ttm)
$400.02M
Revenue Growth
+28.95%
P/S Ratio
3.90
Revenue / Employee
$819,282
Employees
524
Market Cap
1.68B
Revenue by Geography
- United States 257.00M 64.2%
- Europe 131.42M 32.9%
- International 11.60M 2.9%
Fiscal year ended Dec 31, 2025 See the full Immunocore Holdings breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 400.02M | 89.81M | 28.95% |
| Dec 31, 2024 | 310.20M | 60.77M | 24.37% |
| Dec 31, 2023 | 249.43M | 75.53M | 43.44% |
| Dec 31, 2022 | 173.89M | 138.04M | 384.99% |
| Dec 31, 2021 | 35.85M | -5.32M | -12.91% |
| Dec 31, 2020 | 41.17M | 7.13M | 20.95% |
| Dec 31, 2019 | 34.04M | 3.91M | 12.98% |
| Dec 31, 2018 | 30.13M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Ultragenyx Pharmaceutical | 730.00M |
| Nurix Therapeutics | 701.94M |
| Precigen | 156.94M |
| Intellia Therapeutics | 52.89M |
| Generate Biomedicines | 26.48M |
| uniQure | 20.17M |
| Nanobiotix | 13.15M |
| ADARx Pharmaceuticals | 6.13M |
IMCR News
- 7 hours ago - Immunocore price target lowered to $80 from $100 at H.C. Wainwright - TheFly
- 1 day ago - Immunocore to present at upcoming investor conferences - GlobeNewsWire
- 4 days ago - Immunocore presents Phase 1/2 trial cohort data of brenetafusp plus KIMMTRAK - TheFly
- 4 days ago - Immunocore presents promising data from Phase 1/2 trial cohort evaluating brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma - GlobeNewsWire
- 4 days ago - Immunocore reports third quarter financial results and provides a business update - GlobeNewsWire
- 4 days ago - Immunocore Holdings Quarterly report: Q3 2026 - Filings
- 4 days ago - Immunocore Holdings Earnings release: Q3 2026 - Filings
- 4 days ago - Immunocore Holdings Slides: Corporate presentation - Filings